What We're Reading: Page 155
Industry reads hand-picked by our editors
Jun 24, 2021
Jun 23, 2021
-
HuffPost
Can America Finally Do Something On Drug Prices? This Democratic Senator Thinks So.
-
Caixin Global
China Approves Its First CAR-T Cell Therapy
-
Evaluate Vantage
EQRX vows to slash drug prices where others have failed
-
STAT
Peter Bach, industry critic, joins company aiming to make liquid biopsies
Jun 22, 2021
-
The New York Times
New Alzheimer’s Drug Could Cost the Government as Much as It Spends on NASA
-
STAT
BIO's chief on the FDA commissioner rumors, drug pricing, and IP rights
-
Bloomberg
Amarin Rebuffed in High Court Bid to Revive Vascepa Patents
-
The Boston Globe
Pear Therapeutics to go public in $1.6 billion SPAC deal to treat diseases with software
Jun 21, 2021
-
FT
GSK faces struggle to convince investors as activist Elliott lurks
-
The Wall Street Journal
Moderna Plans to Expand Production to Make Covid-19 Vaccine Boosters, Supply More Countries
-
FierceBiotech
Roche's Alzheimer's drug lowers biomarkers of inherited disease
-
C&EN
Vaccines could make big Ebola outbreaks a thing of the past
Jun 18, 2021
-
Timmerman Report
On Juneteenth, Honoring 22 Black Biotech Leaders
-
The Washington Post
How Pfizer engineers overcame early obstacles to produce 3 billion shots
-
STAT
Athira Pharma CEO placed on leave amid claims of altered images
-
Reuters
CureVac may let contractors make rival vaccines if own shot fails - CEO
Jun 17, 2021
-
The New York Times
Vaccine Maker Earned Record Profits but Delivered Disappointment in Return
-
Endpoints News
Danaher strikes deal to buy booming next-gen manufacturer Aldevron for $9.6B
-
Bloomberg
New York Push to Rein In Drug Plans Tests High Court Ruling
-
CNBC
Novartis CEO says future pandemics are bound to happen. Here's how to prepare for the next one
-
Healthcare Dive
Supreme Court upholds ACA in 7-2 decision, leaving intact landmark US health law
Jun 16, 2021
-
Reuters
First patient set to receive controversial Biogen Alzheimer's drug
-
The Wall Street Journal
Lina Khan, Critic of Large Tech Firms, to Lead Federal Trade Commission
-
The Boston Globe
Life sciences is poised to be Boston's dominant industry. Has the area become the Silicon Valley of biotech?
-
In The Pipeline
The Novavax Vaccine Data, and Spike Proteins in General
Previous
